Dig­i­tal ther­a­peu­tics 2023: Swing and tri­al part­ner Cu­rav­it kick off fi­bromyal­gia study

Af­ter the boom-and-bust cy­cling in dig­i­tal ther­a­peu­tics over the past few years, dig­i­tal health providers are look­ing for 2023 to be a sta­bi­liz­ing year. Two of those com­pa­nies are dig­i­tal ther­a­peu­tics de­vel­op­er Swing Ther­a­peu­tics and all-vir­tu­al CRO Cu­rav­it Clin­i­cal Re­search.

The pair are cur­rent­ly en­rolling a tri­al for Swing’s Stan­za, a pre­scrip­tion smart­phone DTx for fi­bromyal­gia. The cog­ni­tive be­hav­ioral ther­a­py treat­ment, which re­ceived a break­through de­vice des­ig­na­tion from the FDA in 2021, be­came avail­able for pa­tients in Sep­tem­ber, along­side the for­mal clin­i­cal tri­al which will fin­ish en­roll­ment soon with the study set to com­plete in the third quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER